<DOC>
	<DOCNO>NCT02645175</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled , parallel study evaluate safety profile ability TW1025 oral solution decrease fatigue HER2-negative metastatic breast cancer patient receive chemotherapy .</brief_summary>
	<brief_title>Evaluate Safety Profile Ability TW1025 Oral Solution Decrease Fatigue</brief_title>
	<detailed_description>The study population design enrol patient histologically and/or cytologically confirm breast cancer clinical evidence recurrent progressive HER2-negative metastatic disease plan begin chemotherapy regimen physician 's choice HER2-negative MBC evidence fatigue . An add-on study design assess superiority TW1025 placebo utilize study evaluate whether TW1025 decrease fatigue patient fatigue . The study conduct double-blind , randomize trial .</detailed_description>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>A patient eligible study follow apply : 1 . Female patient least 18 year age study site United States 20 80 year old ( inclusive ) study sit Taiwan 2 . Histologically and/or cytologically confirm HER2negative breast cancer clinical evidence recurrent progressive metastatic disease 3 . Patients may measurable nonmeasurable metastatic breast cancer . 4 . Planning begin new chemotherapy regimen physician 's choice 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 6 . HER2negative disease per College American Pathologists ( CAP ) guideline ( immunohistochemistry ( IHC ) 0 , 1+ , 2+ fluorescence insitu hybridization ( FISH ) negative ratio &lt; 2.0 ) 7 . Known ER status : ERnegative ( 0 % cell positive ER ) ERpositive ( ≥1 % cell positive ER ) IHC 8 . Adequate bone marrow function ( absolute neutrophil count ≥ 1,500 /µL , hemoglobin count ≥ 8 g/dL , platelet count &gt; 100,000/µL ) , total serum bilirubin &lt; 1.5 mg/dL SGOT/SGPT le 5times upper limit normal liver metastasis present &lt; 2.5times upper limit normal liver metastasis , serum creatinine &lt; 1.5 mg/dL 9 . Fatigue score ≥5 1to10 linear analog scale 10 . Pain score ≤4 1to10 linear analog scale 11 . Insomnia score ≤4 1to10 linear analog scale 12 . If childbearing potential , agree use reliable contraceptive method ( ) participation study 13 . Estimated life expectancy least 6 month 14 . Has provide write informed consent HIPAA authorization Any patient meeting exclusion criterion exclude study participation : 1 . Has receive radiotherapy cytotoxic therapy within 3 week 2 . Any uncontrolled infection 3 . History lupus erythematosus , rheumatoid arthritis , ankylose spondylosis , scleroderma , multiple sclerosis 4 . History known brain metastasis ; Screening brain metastasis require 5 . More 4 prior cytotoxic chemotherapy regimens metastatic disease 6 . Requirement ongoing systemic steroid therapy 7 . Currently use pharmacologic agent nonpharmacologic intervention specifically treat fatigue include psychostimulants , antidepressant , acupuncture , etc . Note : Antidepressants use treat item fatigue ( depression hot flash ) allow patient stable dose ≥ 3 month plan continue ≥ 1 month . Erythropoietin agents treat anemia allow . Exercise allow . 8 . Pain require longacting continuous release narcotic pain medication ; however , shortacting opioids ( oxycodone , hydrocodone ) , tramadol , counter analgesic acetaminophen NSAIDs allow 9 . Use counter herbal/dietary supplement market fatigue energy ( example , product contain type ginseng , rhodiola rosea , high dos caffeine , guarana , anything call `` adaptogen '' ) 10 . Uncontrolled nausea vomit symptom would prevent ability comply daily oral TW1025/placebo treatment 11 . Uncontrolled thyroid disorder 12 . Psychiatric disorder severe depression , manic depressive disorder , obsessive compulsive disorder schizophrenia ( Defined per medical history ) 13 . Any serious diseases/medical history would limit patient 's ability receive study therapy assess investigator 14 . Lactating , pregnant , plan become pregnant 15 . Has receive investigational agent within 4 week enter study 16 . History adverse reaction ingredient TW1025 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Paclitaxel</keyword>
	<keyword>docetaxel</keyword>
	<keyword>vinorelbine</keyword>
	<keyword>eribulin</keyword>
</DOC>